Matinas Biopharma (MTNB) Competitors $0.85 +0.05 (+6.25%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$0.82 -0.03 (-2.94%) As of 05:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MTNB vs. TRIB, COCP, RLYB, ERNA, ABP, EDSA, MBRX, UBX, MEIP, and UPXIShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include Trinity Biotech (TRIB), Cocrystal Pharma (COCP), Rallybio (RLYB), Eterna Therapeutics (ERNA), Abpro (ABP), Edesa Biotech (EDSA), Moleculin Biotech (MBRX), Unity Biotechnology (UBX), MEI Pharma (MEIP), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Trinity Biotech Cocrystal Pharma Rallybio Eterna Therapeutics Abpro Edesa Biotech Moleculin Biotech Unity Biotechnology MEI Pharma Upexi Trinity Biotech (NASDAQ:TRIB) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking. Which has more risk & volatility, TRIB or MTNB? Trinity Biotech has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Do analysts recommend TRIB or MTNB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is TRIB or MTNB more profitable? Matinas Biopharma has a net margin of 0.00% compared to Trinity Biotech's net margin of -34.39%. Trinity Biotech's return on equity of 0.00% beat Matinas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Trinity Biotech-34.39% N/A -21.37% Matinas Biopharma N/A -123.06%-94.28% Do institutionals & insiders have more ownership in TRIB or MTNB? 79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 11.8% of Matinas Biopharma shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by insiders. Comparatively, 4.6% of Matinas Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in TRIB or MTNB? Trinity Biotech received 335 more outperform votes than Matinas Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformTrinity BiotechOutperform Votes33569.79% Underperform Votes14530.21% Matinas BiopharmaN/AN/A Does the media refer more to TRIB or MTNB? In the previous week, Trinity Biotech had 2 more articles in the media than Matinas Biopharma. MarketBeat recorded 2 mentions for Trinity Biotech and 0 mentions for Matinas Biopharma. Matinas Biopharma's average media sentiment score of 0.00 beat Trinity Biotech's score of -0.04 indicating that Matinas Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Trinity Biotech Neutral Matinas Biopharma Neutral Which has higher earnings and valuation, TRIB or MTNB? Matinas Biopharma has lower revenue, but higher earnings than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Matinas Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrinity Biotech$61.56M0.19-$24.02M-$2.82-0.22Matinas Biopharma$1.10M3.93-$22.94M-$3.86-0.22 SummaryTrinity Biotech beats Matinas Biopharma on 8 of the 15 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$4.32M$6.46B$5.34B$19.40BDividend YieldN/A2.65%5.28%3.91%P/E Ratio-0.188.6826.8834.83Price / Sales3.93256.18398.4742.55Price / CashN/A65.8538.2517.51Price / Book0.196.386.764.74Net Income-$22.94M$143.23M$3.22B$1.02B7 Day Performance10.39%2.97%1.50%1.21%1 Month Performance32.61%2.07%7.29%4.99%1 Year PerformanceN/A-0.12%20.28%5.80% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas BiopharmaN/A$0.85+6.3%N/AN/A$4.32M$1.10M-0.1830Gap DownHigh Trading VolumeTRIBTrinity Biotech1.0468 of 5 stars$0.82-3.2%N/A-60.6%$14.80M$59.13M-0.36480Short Interest ↓Gap DownCOCPCocrystal Pharma2.5721 of 5 stars$1.41-0.7%$7.00+396.5%-35.6%$14.44MN/A-0.7610News CoveragePositive NewsShort Interest ↑RLYBRallybio2.7897 of 5 stars$0.35-0.9%$10.00+2,781.8%-78.7%$14.44M$848,000.00-0.2240Gap UpERNAEterna Therapeutics0.7164 of 5 stars$0.23+2.7%N/A-88.0%$14.34M$582,000.00-0.0310News CoverageShort Interest ↑ABPAbproN/A$0.27+18.3%$4.00+1,370.6%N/A$14.20M$183,000.000.0015Positive NewsHigh Trading VolumeEDSAEdesa Biotech2.6913 of 5 stars$2.01-1.0%$21.00+944.8%-53.2%$14.12MN/A-1.0720Short Interest ↓MBRXMoleculin Biotech1.9678 of 5 stars$0.99+5.7%$6.00+503.9%-80.5%$14.04MN/A0.0020Short Interest ↑UBXUnity Biotechnology4.3543 of 5 stars$0.81-1.3%$4.25+425.3%-58.2%$13.93M$240,000.00-0.6260News CoverageAnalyst ForecastGap UpMEIPMEI Pharma2.0441 of 5 stars$2.08flatN/A-30.2%$13.85M$65.30M-0.36100Gap DownUPXIUpexi1.446 of 5 stars$9.64-5.4%N/A-4.2%$13.75M$18.63M0.00130News CoverageShort Interest ↓Gap Up Related Companies and Tools Related Companies TRIB Alternatives COCP Alternatives RLYB Alternatives ERNA Alternatives ABP Alternatives EDSA Alternatives MBRX Alternatives UBX Alternatives MEIP Alternatives UPXI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
